-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
License (licensed cooperation) is a very popular way of product introduction in the pharmaceutical field in recent years
.
At present, Chinese pharmaceutical companies' license-in products have been imported overseas, and the number of license-outs is relatively small
.
But in the past two years, license-out transactions in the pharmaceutical industry have also become active
.
There will be multiple license-out transactions in September 2021
.
For example, on September 8, Biotech announced that it has signed a cooperation agreement with Novartis subsidiary SandozAG (Sandoz) to license part of its self-developed BAT1706 (bevacizumab biosimilar drug) injection to Sandoz for compensation.
Including the United States, Europe, Canada and most other international markets not covered by BAT1706 cooperation
.
On September 8, Luye Pharmaceutical Group announced that its subsidiary Luye Pharmaceuticals (Switzerland) and Esteve Pharmaceuticals, SA (ESTEVE) have reached a cooperation agreement, granting ESTEVE the exclusive commercialization right to develop the Mindo Day transdermal patch in Liss in Spain
.
On September 26, GenScript Biosciences announced that it has reached a cooperation with AskGene, authorizing AskGene to target a non-exclusive global license of single-domain antibodies targeting an immune checkpoint for the discovery, development and commercialization of its antibodies and derivatives
.
Since entering October this year, license-out transactions have also been active
.
For example, on October 29, Fosun Pharma issued an announcement stating that its controlling subsidiary, Fotron Pharmaceuticals, had signed a "License Agreement" with Eli Lilly Pharmaceuticals (NYSE: LLY), granting Eli Lilly the choice of BCL-2 for Fotron Pharmaceuticals.
The molecular inhibitor FCN-338 has exclusive rights in other regions of the world except Mainland China, Hong Kong and Macau
.
According to the "License Agreement", Eli Lilly will pay Fotron Pharmaceuticals a down payment of US$40 million and up to US$400 million in development and sales milestone payments, and pay Fotron Pharmaceuticals based on the annual net sales in the area of Eli Lilly Pharmaceuticals.
Sales commissions in the mid-to-high single-digit range, totaling US$440 million
.
On October 11, Biocytometer’s wholly-owned subsidiary, Youhe Pharmaceuticals, announced that it has signed a strategic cooperation agreement with TRACON Pharmaceuticals (hereinafter referred to as "TRACON").
TRACON will be responsible for YH001's treatment of soft tissue sarcoma in North America, mainly in the United States.
For the clinical development and commercialization of the agreed indications, Youhe Pharmaceutical will retain the development and commercialization rights of other indications in North America
.
YH001 is a humanized IgG1 monoclonal antibody targeting CTLA-4.
It enhances the body's own immune response against tumor cells and strengthens the removal of regulatory T cells (Treg) in the tumor microenvironment, thereby achieving therapeutic benefits.
The purpose of this tumor
.
In this cooperation, TRACON will bear the clinical development costs of the cooperative indications in North America
.
Youhe Pharmaceuticals will supply YH001 medicines to TRACON at negotiated prices, and will receive a tiered double-digit percentage of North American net sales from TRACON for royalties
.
Shanghai Pharmaceuticals Group Co.
, Ltd.
recently issued an announcement stating that the company and HUYABIO INTERNATIonAL (hereinafter referred to as "HUYABIO") have signed a formal agreement on "Shanghai Pharmaceuticals Licenses the Overseas Rights and Interests of SPH6162 to HUYABIO"
.
In this license-out cooperation, HUYABIO intends to pay a milestone payment of no more than US$292.
5 million plus a 3-6% sales commission to obtain the exclusive product development, production and sales of Shanghai Pharmaceutical’s new anti-tumor drug SPH6162 outside of China.
Authorization and the right to sublicense
.
In addition, the two parties also expect to establish a joint development committee to coordinate the development and commercialization of global products
.
This is the first overseas licensing project of Shanghai Pharmaceuticals, and it is also a milestone event that marks the significant progress of the company's R&D and innovation capabilities
.
Some analysts said that after the rapid and vigorous development of China's pharmaceutical industry in recent years, it has received more and more international attention and recognition.
The development of innovative drug projects has changed from license in to license out.
Cross-border cooperation is becoming more frequent, the scale of transactions is getting bigger and bigger, and the forms of cooperation are becoming more and more diversified
.
.
At present, Chinese pharmaceutical companies' license-in products have been imported overseas, and the number of license-outs is relatively small
.
But in the past two years, license-out transactions in the pharmaceutical industry have also become active
.
There will be multiple license-out transactions in September 2021
.
For example, on September 8, Biotech announced that it has signed a cooperation agreement with Novartis subsidiary SandozAG (Sandoz) to license part of its self-developed BAT1706 (bevacizumab biosimilar drug) injection to Sandoz for compensation.
Including the United States, Europe, Canada and most other international markets not covered by BAT1706 cooperation
.
On September 8, Luye Pharmaceutical Group announced that its subsidiary Luye Pharmaceuticals (Switzerland) and Esteve Pharmaceuticals, SA (ESTEVE) have reached a cooperation agreement, granting ESTEVE the exclusive commercialization right to develop the Mindo Day transdermal patch in Liss in Spain
.
On September 26, GenScript Biosciences announced that it has reached a cooperation with AskGene, authorizing AskGene to target a non-exclusive global license of single-domain antibodies targeting an immune checkpoint for the discovery, development and commercialization of its antibodies and derivatives
.
Since entering October this year, license-out transactions have also been active
.
For example, on October 29, Fosun Pharma issued an announcement stating that its controlling subsidiary, Fotron Pharmaceuticals, had signed a "License Agreement" with Eli Lilly Pharmaceuticals (NYSE: LLY), granting Eli Lilly the choice of BCL-2 for Fotron Pharmaceuticals.
The molecular inhibitor FCN-338 has exclusive rights in other regions of the world except Mainland China, Hong Kong and Macau
.
According to the "License Agreement", Eli Lilly will pay Fotron Pharmaceuticals a down payment of US$40 million and up to US$400 million in development and sales milestone payments, and pay Fotron Pharmaceuticals based on the annual net sales in the area of Eli Lilly Pharmaceuticals.
Sales commissions in the mid-to-high single-digit range, totaling US$440 million
.
On October 11, Biocytometer’s wholly-owned subsidiary, Youhe Pharmaceuticals, announced that it has signed a strategic cooperation agreement with TRACON Pharmaceuticals (hereinafter referred to as "TRACON").
TRACON will be responsible for YH001's treatment of soft tissue sarcoma in North America, mainly in the United States.
For the clinical development and commercialization of the agreed indications, Youhe Pharmaceutical will retain the development and commercialization rights of other indications in North America
.
YH001 is a humanized IgG1 monoclonal antibody targeting CTLA-4.
It enhances the body's own immune response against tumor cells and strengthens the removal of regulatory T cells (Treg) in the tumor microenvironment, thereby achieving therapeutic benefits.
The purpose of this tumor
.
In this cooperation, TRACON will bear the clinical development costs of the cooperative indications in North America
.
Youhe Pharmaceuticals will supply YH001 medicines to TRACON at negotiated prices, and will receive a tiered double-digit percentage of North American net sales from TRACON for royalties
.
Shanghai Pharmaceuticals Group Co.
, Ltd.
recently issued an announcement stating that the company and HUYABIO INTERNATIonAL (hereinafter referred to as "HUYABIO") have signed a formal agreement on "Shanghai Pharmaceuticals Licenses the Overseas Rights and Interests of SPH6162 to HUYABIO"
.
In this license-out cooperation, HUYABIO intends to pay a milestone payment of no more than US$292.
5 million plus a 3-6% sales commission to obtain the exclusive product development, production and sales of Shanghai Pharmaceutical’s new anti-tumor drug SPH6162 outside of China.
Authorization and the right to sublicense
.
In addition, the two parties also expect to establish a joint development committee to coordinate the development and commercialization of global products
.
This is the first overseas licensing project of Shanghai Pharmaceuticals, and it is also a milestone event that marks the significant progress of the company's R&D and innovation capabilities
.
Some analysts said that after the rapid and vigorous development of China's pharmaceutical industry in recent years, it has received more and more international attention and recognition.
The development of innovative drug projects has changed from license in to license out.
Cross-border cooperation is becoming more frequent, the scale of transactions is getting bigger and bigger, and the forms of cooperation are becoming more and more diversified
.
